Малта - английски - Medicines Authority

gap s.a 46, agissilaou street, 17341 agios dimitrios, athens, greece - film-coated tablet - vildagliptin 50 mg metformin hydrochloride 1000 mg - drugs used in diabetes

Малта - английски - Medicines Authority

galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - film-coated tablet - vildagliptin 50 mg metformin hydrochloride 850 mg - drugs used in diabetes

Малта - английски - Medicines Authority

galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - film-coated tablet - sitagliptin 50 mg metformin hydrochloride 850 mci - drugs used in diabetes

Малта - английски - Medicines Authority

galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - film-coated tablet - sitagliptin 50 mg metformin hydrochloride 1000 mg - drugs used in diabetes

Малта - английски - Medicines Authority

pharmacare srl via marghera, 29 20149, milan, italy - film-coated tablet - sitagliptin 50 mg metformin hydrochloride 850 mg - drugs used in diabetes

Малта - английски - Medicines Authority

pharmacare srl via marghera, 29 20149, milan, italy - film-coated tablet - sitagliptin 50 mg metformin hydrochloride 1000 mg - drugs used in diabetes

Израел - английски - Ministry of Health

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - film coated tablets - linagliptin 2.5 mg; metformin hydrochloride 1000 mg - metformin - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajenta-duo should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. trajenta-duo has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trajenta-duo.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - metformin hydrochloride, quantity: 1000 mg; linagliptin, quantity: 2.5 mg - tablet, film coated - excipient ingredients: copovidone; propylene glycol; magnesium stearate; arginine; iron oxide red; hypromellose; colloidal anhydrous silica; titanium dioxide; maize starch; purified talc - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate, in patients inadequately controlled on metformin alone, or those already being treated and well controlled with the free combination of linagliptin and metformin. trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea. trajentamet is indicated in combination with an sglt2 inhibitor (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor. trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - metformin hydrochloride, quantity: 1000 mg; linagliptin, quantity: 2.5 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; propylene glycol; maize starch; purified talc; hypromellose; iron oxide red; arginine; magnesium stearate; titanium dioxide; copovidone - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate, in patients inadequately controlled on metformin alone, or those already being treated and well controlled with the free combination of linagliptin and metformin. trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea. trajentamet is indicated in combination with an sglt2 inhibitor (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor. trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.

Малта - английски - Medicines Authority

alfred e. tiefembacher (gmbh &co. kg) - vildagliptin; metformin hydrochloride - film-coated tablet - vildagliptin 50 mg; metformin hydrochloride 850 mg - drugs used in diabetes